Theralase Technologies (TTX) Financial Statements
Theralase Technologies Financial Overview
Theralase Technologies's market cap is currently $35.69M. The company's EPS TTM is $-0.01; its P/E ratio is -12.68; Theralase Technologies is estimated to report earnings on December 2, 2026, and the estimated EPS forecast is $-0.00. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Dec 24 | Dec 23 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 816.47K | $ 1.03M | $ 1.07M | $ 1.14M | $ 780.64K |
| Gross Profit | $ 241.51K | $ 554.03K | $ 562.13K | $ 628.17K | $ 309.94K |
| Operating Income | $ -4.18M | $ -4.29M | $ -4.59M | $ -5.20M | $ -4.52M |
| EBITDA | $ -3.91M | $ -3.96M | $ -4.25M | $ -4.90M | $ -4.31M |
| Net Income | $ -4.12M | $ -4.26M | $ -4.57M | $ -5.25M | $ -4.42M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 182.91K | $ 268.76K | $ 43.91K | $ 1.51M | $ 3.69M |
| Total Assets | $ 3.49M | $ 3.25M | $ 3.28M | $ 4.16M | $ 5.94M |
| Total Debt | $ 458.05K | $ 293.87K | $ 386.88K | $ 473.62K | $ 35.72K |
| Net Debt | $ 275.14K | $ 25.11K | $ 342.97K | $ -1.03M | $ -3.66M |
| Total Liabilities | $ 1.72M | $ 1.18M | $ 1.37M | $ 1.07M | $ 874.79K |
| Stockholders' Equity | $ 1.78M | $ 2.07M | $ 1.91M | $ 3.09M | $ 5.07M |
| Cash Flow | |||||
| Free Cash Flow | $ -3.33M | $ -3.35M | $ -4.11M | $ -5.20M | $ -4.13M |
| Operating Cash Flow | $ -3.29M | $ -3.33M | $ -4.07M | $ -5.13M | $ -4.03M |
| Investing Cash Flow | $ -48.94K | $ -19.97K | $ -37.27K | $ -70.41K | $ -100.82K |
| Financing Cash Flow | $ 3.25M | $ 3.57M | $ 2.65M | $ 3.02M | $ -57.37K |
Currency in CAD